Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases

Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SUZUKI, HIDEKAZU, HIRASHIMA, TOMONORI, KOBAYASHI, MASASHI, OKAMOTO, NORIO, MATSUURA, YUKA, TAMIYA, MOTOHIRO, MORISHITA, NAOKO, OKAFUJI, KOHEI, SHIROYAMA, TAKAYUKI, MORIMURA, OSAMU, MORITA, SATOMU, KAWASE, ICHIRO
Format: Artigo
Sprache:Inglês
Veröffentlicht: D.A. Spandidos 2013
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3915637/
https://ncbi.nlm.nih.gov/pubmed/24649195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2013.82
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge